RxDoctor Payments DataLook up a doctor →

Salil Sethi, MD

Interventional Cardiology · Sun City West, AZNPI 1164665477

Payments from drug & device makers

$43,610in general payments, 2019–2025

Across 475 payments — averaging $91.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$21K
  • Medtronic$4K
  • Penumbra, Inc.$3K
  • Cardiovascular Systems Inc.$3K
  • Abiomed$2K
  • Abbott$2K
  • plus $9K from 40 others

What the payments were for

  • Consulting fees$14,84034%
  • Speaking & faculty fees$3,9159%
  • Travel & lodging$6,30914%
  • Food & beverage$18,25542%
  • Education$2921%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$43,610 in reported general payments places this provider in the 75th percentile of 223 interventional cardiology providers in Arizona.

See all interventional cardiology providers in Arizona

Medicare billing

Part B allowed, 2024
$751,788
Medicare patients
1,089
Services billed
8,599

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban368$482,301
EntrestoSacubitril/Valsartan86$137,271
XareltoRivaroxaban104$115,707
BrilintaTicagrelor121$106,050
Repatha SureclickEvolocumab46$36,449
JardianceEmpagliflozin20$25,344
Repatha PushtronexEvolocumab16$23,694
MultaqDronedarone Hcl26$16,586
Praluent PenAlirocumab12$12,801
Metoprolol Succinate816$9,466
ClopidogrelClopidogrel Bisulfate625$8,425
Rosuvastatin Calcium571$7,903
Atorvastatin Calcium611$5,867
Ranolazine ErRanolazine40$4,543
Amlodipine Besylate619$3,932

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$234$482,301368 claims
NovartisEntresto$401$137,27186 claims
Johnson & JohnsonXarelto$582$115,707104 claims
AstraZenecaBrilinta$64$106,050121 claims
Boehringer IngelheimJardiance$192$25,34420 claims
Sanofi-aventis U.S. LLCMultaq$221$16,58626 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 223 interventional cardiology providers in Arizona.

Other interventional cardiology in Sun City West

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →